Print

AnGes MG Inc. Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma Corporation for Exclusive Marketing Rights of Collategene® in the United States  
10/24/2012 8:44:31 AM

TOKYO, Oct. 24, 2012 (GLOBE NEWSWIRE) -- AnGes MG Inc. ("AnGes") announced today that the company has entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, President & CEO, Michihiro Tsuchiya, "MTPC") for the exclusive marketing rights of Collategene® (DNA Plasmid with HGF gene) as a treatment for Peripheral Arterial Disease (PAD) in the United States.